Scilex Holding (SCLXW) Amortization of Deferred Charges (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Amortization of Deferred Charges of $1.0 million in Q1 2026, up 151.34% quarter-over-quarter from $409000.0 in Q4 2025.
Scilex Holding (SCLXW) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Scilex Holding's Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges changed N/A year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.4 million (up 404.21% YoY), while the FY2025 annual figure was $409000.0, up 29.43% from the prior year.
- Amortization of Deferred Charges was $1.0 million for Q1 2026 at Scilex Holding, up from $409000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $1.9 million in Q1 2022 to a low of $1000.0 in Q2 2023.
- Historically, Amortization of Deferred Charges has averaged $381538.5 across 5 years, with a median of $34000.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges slumped 99.92% in 2023, then surged 3100.0% in 2024.
- A 5-year view of Amortization of Deferred Charges shows it stood at $34000.0 in 2022, then retreated by 8.82% to $31000.0 in 2023, then soared by 616.13% to $222000.0 in 2024, then surged by 84.23% to $409000.0 in 2025, then soared by 151.34% to $1.0 million in 2026.
- The last three Amortization of Deferred Charges figures came in at $1.0 million (Q1 2026), $409000.0 (Q4 2025), and $222000.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 Mn |
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | 409,000.00 |
| Dec 31, 2025 | 409,000.00 |
| Dec 31, 2024 | 222,000.00 |
| Dec 31, 2024 | 222,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Dec 31, 2022 | 34,000.00 |
| Dec 31, 2022 | 34,000.00 |